The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration

Thrombosis and Haemostasis

Volumn 86, Issue 4, 2001, Pages 1035-1039

  Mosnier, L O ^a   Lisman, T ^a   Van Den Berg, H M ^a   Nieuwenhuis, H K ^a   Meijers, J C M ^a   Bouma, B N ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Carboxypeptidase U; Coagulation; Factor VIII; Fibrinolysis; Haemophilia A; Thrombin activatable fibrinolysis inhibitor (TAFI)

Indexed keywords

BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; FIBRIN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR;

ANTIBODY TITER; ARTICLE; BLEEDING DISORDER; BLOOD CLOT LYSIS; BLOOD CLOTTING; BLOOD CLOTTING TEST; BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; FIBRINOLYSIS; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; METABOLIC ACTIVATION; PLASMA; PRIORITY JOURNAL;

EID: 0034757342     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616530     Document Type: Article

References (23)

1. Haemophilia A
2. Haemophilia and related inherited coagulation defects
3. The tissue factor pathway: How it has become a "prima ballerina"
4. Selective cellular expression of tissue factor in human tissues: Implications for disorders of hemostasis and thrombosis
5. The haemostatic plug in haemophilia A: A morphological study of haemostatic plug formation in bleeding time skin wounds of patients with severe haemophilia A
6. Factor XI and protection of the fibrin clot against lysis. A role for the intrinsic pathway of coagulation in fibrinolysis
7. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor
8. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen
9. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma
10. Plasma carboxypeptidases as regulators of the plasminogen system
11. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis
12. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis
13. Coagulation-dependent inhibition of fibrinolysis: Role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma
14. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex
15. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent
16. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin
17. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact pathway of coagulation
18. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma
19. The Recombinate study group: A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A
20. Plasma TAFI antigen variations in health subjects
21. Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains
22. Elements of the primary structure of thrombomodulin required for efficient TAFI activation
23. Tranexamic acid in control of haemorrhage after dental extraction in haemophilia and Christmas disease